mTOR Inhibitor XIII; ETP-46464

Code: 5005080001 D2-231

Biochem/physiol Actions

Reversible: yes

Primary TargetATR

Cell permeable: yes

General description

A cell-permeable quinoline-containi...


read more

Your Price
€268.12 EACH
€329.79 inc. VAT

Biochem/physiol Actions

Reversible: yes

Primary TargetATR

Cell permeable: yes

General description

A cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα, and ATM activity (IC50 = 0.6, 14, 36, 170, and 545 nM, respectively, in cell-free kinase assays) and preferentially suppresses ionization radiation/IR-induced cellular ATR activity (>90% inhibition of IR-induced Chk1 pSer345 at 500 nM) over ATM or DNA-PK activity (IC50 >5 µM against IR-induced ATM pSer189, Chk2 pThr68, DNA-PKcs pSer2056, and γH2AX) in U2OS cells, while exhibiting much reduced or little potency toward a panel of 26 other kinases (>55% inhibition at 5 µM). Shown to synergize with UCN-01 (Cat. No. 539644) in replicative stress/RS induction in S-phase replicating U2OS (% population with pan-nuclear γH2AX staining = 6.0% and 0.2%, respectively, with or without 8 h 5 µM ETP-46464 treatment; 1.5-, 61-, and 190-fold of control RS, respectively, with 1 µM ETP-46464 alone, 50 nM UCN-01 alone, or combined treatment). Likewise, ETP-46464 is also demonstrated to further enhance oncogenic mutations-caused RS elevation in MEF cultures (% RS population without/with 5 µM ETP-46464 treatment = 0.3/0.6, 1.3/2.5, 0.9/3.0, 3.9/11.4, respectively, in wt, p53-/-, Cyclin E-transfected wt, and Cyclin E-transfected p53-/- MEF).

A cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα, and ATM (IC50 = 0.6, 14, 36, 170, and 545 nM, respectively) and preferentially suppresses radiation-induced cellular ATR activity (>90% at 500 nM) over ATM or DNA-PK activity (IC50 >5 M) in U2OS cells, while exhibiting much reduced or little potency toward a panel of 26 other kinases (>55% inhibition at 5 M). Shown to synergize with UCN-01 (Cat. No. 539644) in replicative stress induction in S-phase replicating U2OS (1.5-, 61-, and 190-fold of control RS, respectively, with 1 M ETP-46464, 50 nM UCN-01, or combined treatment).Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Thanasoula, M., et al. 2012. EMBO J.31, 3398.Toledo, L.I., et al. 2011. Nat Struct Mol Biol.18, 721.

Packaging

Packaged under inert gas

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)

assay≥99% (HPLC)
colorwhite
formpowder
manufacturer/tradenameCalbiochem®
potency14 nM IC50
Quality Level100
solubilityDMSO: 10 mg/mL
storage conditionprotect from light, OK to freeze
storage temp.2-8°C
Cas Number345675-02-7
This product has met the following criteria to qualify for the following awards:



PROCEED TO CHECKOUT

HAVE AN ACCOUNT? LOGIN


GUEST CHECKOUT

Proceed as a guest. You will have the option to register to access exclusive pricing and stock availability features after checkout.